AI brief of an SEC Form 8-K · Concentrix (CNXC)

Concentrix restates credit agreement with $1.1 billion revolver, $750 million term loan

Neutral Impact 3 of 5 financing Written later

Concentrix entered into an Amendment and Restatement Agreement on April 11, 2025, with Bank of America, N.A. taking over as administrative agent from JPMorgan Chase Bank, N.A. The restated credit agreement provides a $1.1 billion revolving facility, a $750 million unsecured term loan, and up to $750 million of delayed draw term loans, and the company also amended its receivables securitization facility. For shareholders, the filing sets new debt terms and maturities, and the company intends to use the delayed draw loans to repay a €700 million promissory note issued for the Webhelp combination.

Key points

  • Revolving credit facility of up to $1.1 billion, maturing April 11, 2030
  • New $750 million three-year term loan, with $250 million three-year and $500 million five-year delayed draw term loans that must be funded by September 30, 2025
  • Delayed draw loan proceeds intended to repay in full a €700 million promissory note issued to sellers in the September 2023 Webhelp combination
  • Financial covenants require a consolidated leverage ratio of no more than 3.75 to 1.00 and an interest coverage ratio of at least 3.00 to 1.00

The filing

CompanyConcentrix (CNXC)
Form8-K, current report
Filed with the SECApr 11, 2025, 4:03 PM ET
Accession number0001803599-25-000111

Items reported: 1.01 Material Definitive Agreement2.03 New Direct Financial Obligation8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:54 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.